Milnacipran Glenmark (Milnacipran Hydrochloride)

Milnacipran Hydrochloride, the active ingredient in Milnacipran Glenmark, is a serotonin‑norepinephrine reuptake inhibitor (SNRI) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Milnacipran Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Milnacipran Glenmark is an SNRI antidepressant used to address mood disorders within the depressive disease spectrum.

Major depressive disorder: reduces depressive symptoms and improves functional outcomes in adult patients.

Milnacipran may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea - Headache - Constipation - Dry mouth - Insomnia - Dizziness

Serious or Rare Side Effects: - Elevated blood pressure or hypertension - Serotonin syndrome, especially when combined with other serotonergic agents - Suicidal thoughts or behavior, particularly early in treatment - Severe liver injury (rare) - Cardiac arrhythmias

When prescribing Milnacipran, clinicians should consider several safety measures.

Assess cardiovascular status: monitor blood pressure and heart rate regularly. Screen for suicidal ideation: closely observe patients during the initial treatment period. Avoid abrupt discontinuation: taper the dose under medical supervision to reduce withdrawal risk. Use caution in hepatic impairment: adjust dosing if liver function is compromised. Avoid concomitant MAO inhibitors: ensure an appropriate washout period before initiating therapy. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Milnacipran can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertensive crisis. - Other serotonergic agents (SSRIs, SNRIs, tricyclic antidepressants, tramadol, triptans): potential for serotonin syndrome. - Sympathomimetic agents (e.g., decongestants, pseudoephedrine): may exacerbate hypertension.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: additive blood‑pressure‑lowering effect. - CYP2D6 substrates (e.g., metoprolol): possible alteration of plasma levels. - NSAIDs or anticoagulants: increased risk of bleeding.